Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 24Thoracic 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Stomach Neoplasms 1Lung Neoplasms 1Carcinoma, Transitional Cell 1Adenocarcinoma 1

Interventions

pembrolizumab 39Nivolumab 13Cisplatin 12Paclitaxel 11Docetaxel 11Carboplatin 10atezolizumab 9Trastuzumab 9Gemcitabine 9Cyclophosphamide 8fludarabine 7Bevacizumab 7aldesleukin 6durvalumab 5Taxes 5Oxaliplatin 5Magnetic Resonance Spectroscopy 5Leucovorin 5Irinotecan 5Fluorouracil 5130-nm albumin-bound paclitaxel 5avelumab 4Specimen Handling 4Psychiatric Rehabilitation 4Ipilimumab 4Drug Therapy 4Cetuximab 4Capecitabine 4Albumin-Bound Paclitaxel 4tislelizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × Tegafur × Thoracic × Clear all
NCT05867121 2026-04-27

A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

Genentech, Inc.

Phase 1 Active not recruiting
102 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡